莱沃多巴添加到中风康复:ESTREL随机临床试验
Stefan T Engelter1,2, Josefin E Kaufmann1,2, Annaelle Zietz1,2
1Department of Rehabilitation and Neurology, University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Basel, Switzerland.
JAMA
|September 22, 2025
概括
在接受康复的中风患者中,利沃多巴没有改善运动功能. 这项随机试验表明,在加于标准治疗时,利沃多巴不能有效增强急性中风后的运动恢复.
科学领域:
- 神经科学
- 临床神经学
- 康复医学
背景情况:
- 利沃多巴增强多巴胺信号传递,并可能促进神经可塑性,这表明它对中风后的运动恢复有潜在的益处.
- 目前在中风康复中使用利沃多巴的证据不尽相同.
研究的目的:
- 为了评估多巴,当添加到标准化康复,与安慰剂相比,改善急性中风患者的运动恢复.
- 这项研究旨在提供关于利沃多巴在中风后运动康复中的作用的确证据.
主要方法:
- 一个双盲,安慰剂对照的随机临床试验,涉及610名急性中风和半衰竭患者.
- 参与者每天接受三次levodopa/carbidopa或安慰剂,同时接受积极的任务导向训练.
- 主要结局指标是3个月后Fugl- Meyer评估 (FMA) 总得分的变化.
主要成果:
- 在3个月后,在乐沃多巴组和安慰剂组之间没有明显的运动功能差异 (平均差异为- 0. 90分;P=.54).
- 在乐沃多巴组中,FMA的中位数为68,而在安慰剂组中为64.
- 严重的不良事件在两组之间是相似的,感染是最常见的.
结论:
- 在接受标准化康复治疗时,利沃多巴并没有显著改善急性中风患者的运动功能恢复.
- 这些发现不支持经常使用利沃多巴作为辅助治疗,以改善中风后的运动结果.
更多相关视频
07:35Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System
Published on: December 29, 2023
1.8K
05:28Author Spotlight: Enhancing Upper Limb Rehabilitation in Stroke Patients Through Advanced Robotic and Neuromodulation Technologies
Published on: October 11, 2024
1.1K
相关概念视频
Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
